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The  SeDeM  diagram  expert  system  has  been  used  to  study  excipients,  Captopril  and  designed  formulations
for  their  galenic  characterization  and  to ascertain  the  critical  points  of  the  formula  affecting  product
quality  to obtain  suitable  formulations  of Captopril  direct compression  SR  matrix  tablets.
The  application  of  the  SeDeM  diagram  expert  system  enables  selecting  excipients  with  in order  to
optimize  the  formula  in  the  preformulation  and  formulation  studies.
The  methodology  is based  on the  implementation  of  ICH  Q8, establishing  the  design  space of  the  formula
with  the  use  of  experiment  design,  using  the  parameters  of the SeDeM  diagram  expert  system  as  system
responses.
© 2013 Published by Elsevier B.V.
1. Introduction26
The SeDeM Method (Sun˜é-Negre et al., 2005) is a new galenic27
method for application in tablet-preformulation and formulation28
studies. It provides information about the suitability of active29
ingredients and excipients in powder for direct compression. This30
information indicates the degree to which the substances can be31
successfully compressed by means of direct-compression technol-32
ogy. The SeDeM method makes it possible to detect the powder33
properties that need to be adjusted to facilitate the formulation34
of the end product for direct compression. The SeDeM method is35
therefore also a useful tool for studying the reproducibility of the36
process used to prepare a powder substance and, consequently, for37
its validation (Pérez-Lozano et al., 2006).38
Furthermore, it has been shown to be a suitable tool for prefor-39
mulation and formulation by characterizing the galenic properties40
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of excipients in order to deﬁne their suitability for direct compres- 41
sion (Aguilar et al., 2009; Sun˜é-Negre et al., 2008) 42
The SeDeM diagram expert system is based on the concept of 43
quality by design described in ICH Q8 (EMEA, 2004) since it eval- 44
uates critical quality attributes that have an impact on the quality 45
of the ﬁnal product. The SeDeM diagram expert system provides 46
the proﬁle of excipients and active product ingredients (API) in 47
powder form with respect to their suitability for direct compres- 48
sion. This proﬁle indicates whether a powder can successfully be 49
compressed by direct compression technology or whether it needs 50
to be adjusted with appropriate additional excipients. In addition, 51
this SeDeM diagram expert system could be seen as an innovative 52
quality by design (ICH Q8) tool, since it evaluates factors that are 53
not studied in the traditional drug formulation method and pro- 54
vides information about which properties can be improved. Thus, 55
this tool helps the formulator to design robust processes which can 56
inﬂuence the quality of the ﬁnal product when it is marketed. 57
Captopril is an angiotensine-converting enzyme inhibitor that 58
has been widely used for the treatment of hypertension and con- 59
gestive heart failure. Captopril acts orally and the dosage used for 60
the treatment of congestive heart failure ranges from 50 to 150 mg 61
daily. After oral ingestion of a single dose the maximum hemody- 62
namic effect is observed after 45–90 min. The drug is freely water 63
0378-5173/$ – see front matter ©  2013 Published by Elsevier B.V.
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Table 1
Parameters and equations used in SeDeM methodology.
Incidence Parameter Symbol Unit Equation
Dimension Bulk density Da g/ml Da = P/Va
Tapped density Dc g/ml Dc = P/Vc
Compressibility Inter-particle porosity Ie – Ie = Dc − Da/Dc × Da
Carr index IC % IC = (Dc − Da/Dc) 100
Cohesion indexa Icd N Experimental
Flowability/powder ﬂow Hausner ratio IH – IH = Dc/Da
Angle of repose (˛) ◦ Tg˛ = h/r
Powder ﬂow t′′ s Experimental
Lubricity/stability Loss on drying %HR % Experimental
Hygroscopicity %H % Experimental
Lubricity/dosage  Particles < 50 m % PF % Experimental
Homogeneity indexb (I) – Eq. (1)
a Hardness (N) of the tablets obtained with the product in question, alone or blended with lubricants if highly abrasive.
b Determines particle size. In accordance with the percentages of the different particle-size fractions by applying Eq. (1).
soluble and has elimination half-life after an oral dose of 1.7 h. It is64
stable at pH 1.2, and as the pH increases, the drug becomes unstable65
and undergoes a degradation reaction. Captopril has been the drug66
of choice in hypertension management. However, after a single oral67
dosage of the drug, the antihypertensive action is only effective for68
6–8 h. Development of a controlled delivery system for Captopril69
is difﬁcult because of in vivo and in vitro instability. The drug70
also undergoes dose dumping and burst phenomenon (being freely71
water soluble) when formulated as a controlled or sustained release72
formulation (Jiménez-Martínez et al., 2008).73
The concept of the ICH Q8 guideline is based on deﬁning a74
design space. The aim of this paper is to establish a design space75
that enables knowing the system using the SeDeM diagram expert76
system as a critical attribute of product quality.77
In another article it will explain the design of experiments with78
the aim of establishing the design space in the dissolution test as79
the product’s most important critical attribute. In this paper we80
use the same variables but taking as answers the variables of the81
SeDeM diagram expert system, with the ﬁnal goal of understanding82
the behavior of the system from a pharmacotechnical viewpoint.83
2. Product characterization using the SeDeM method84
As established in earlier studies (Pérez-Lozano et al., 2006;85
Sun˜é-Negre et al., 2005) the SeDeM Method is based on the86
experimental study and quantitative determination of the char-87
acterization parameters of powdered substances that provide the88
necessary information about a substance’s appropriateness for89
obtaining tablets using direct-compression technology.90
The parameters considered are the following:91
• Bulk density (Da)92
• Tapped density (Dc)93
• Inter-particle porosity (Ie)94
• Carr index (IC)95
• Cohesion index (Icd)96
• Hausner ratio (IH)97
• Angle of repose (˛)98
• Powder ﬂow (t′′)99
• Loss on drying (% HR)100
• Hygroscopicity (%H)101
• Particle size (%Pf)102
• Homogeneity index (I) 103
These parameters are determined by means of the new SeDeM 104
diagram method, based on known equations (Pérez-Lozano et al., 105
2006; Sun˜é-Negre et al., 2005, 2011a, 2011b)  and duly validated 106
and reproducible experimental tests, as shown in Table 1. 107
Eq. (1) named in Table 1 is 108
I = Fm
100 + (dm − dm−1)Fm−1 + (dm+1 − dm)Fm+1 + (dm − dm−2)Fm−2 + . . . + (dm − dm−n)Fm−n + (dm+n − dm)Fm+n
(1) 109
where 110
I: Relative homogeneity index. Particle-size homogeneity in the 111
range of the fractions under study. 112
Fm: Percentage of particles in the majority range. 113
Fm − 1: Percentage of particles in the range immediately below the 114
majority range; Fm+1: Percentage of particles in the range imme- 115
diately above the majority range. 116
n: Order number of the fraction under study, within a series, with 117
respect to the majority fraction. 118
dm: Mean diameter of the particles in the majority fraction. 119
dm − 1: Mean diameter of the particles in the fraction of the range 120
immediately below the majority range. 121
dm + 1: Mean diameter of the particles in the fraction of the range 122
immediately above the majority range. 123
Once the values have been obtained following the speciﬁc 124
methods, certain limits are set based on the study of the chosen 125
parameters and the values described in the handbook of pharma- 126
ceutical excipients (Rowe et al., 2009) (see Table 2). The next step 127
is to convert the numeric limits for each SeDeM Diagram param- 128
eter to radius values r, in accordance with Table 2 (Aguilar et al., 129
2009, 2012; Pérez-Lozano et al., 2006; Sun˜é-Negre et al., 2005, 130
2008, 2011a,b). 131
When all radius values are 10, the SeDeM Diagram takes the 132
form of a circumscribed regular polygon, drawn by connecting the 133
radius values with linear segments. The results obtained from the 134
earlier parameter calculations and conversions are represented by 135
the radius. The ﬁgure formed indicates the characteristics of the 136
product and of each of the parameters that determine whether or 137
not the product is suitable for direct compression. In this case, the 138
SeDeM Diagram is made up of 12 parameters, which would form 139
an irregular 12-sided polygon. 140
To determine whether or not the product is acceptable for direct 141
compression in numerical form, the following indexes are calcu- 142
lated based on the SeDeM Diagram as: 143
Parameter index(IP)IP = No.p≥5
No.Pt
(2) 144
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Table 2
Conversion of limits for each parameter into radius values (r).
INCIDENCE Parameter Limit value Radius (r) Factor applied to v
Dimension Bulk density 0–1 g/ml 0–10 10v
Tapped density 0–1g/ml 0–10 10v
Compressibility Inter-particle porosity 0–1.2 0–10 10v/1.2
Carr  index 0–50 (%) 0–10 v/5
Cohesion index 0–200 (N) 0–10 v/20
Flow  ability/powder ﬂow Hausner ratio 1–3 10–0 5(3 − v)a
Angle of repose 50–0 (◦) 0–10 10 − (v/5)
Powder ﬂow 20–0 (s) 0–10 10− (v/2)
Lubricity/stability Loss on drying 0–10 (%) 10–0 10 − v
Hygroscopicity 20–0 (%) 0–10 10 − (v/2)
Lubricity/dosage Particles < 50 m 50–0 (%) 0–10 10 − (v/5)
Homogeneity index 0–2 × 10−2 0–10 500v
a Same equation than (30–10 v)/2, but simpliﬁed.
No. p ≥ 5: Indicates the number of parameters whose value is equal145
to or higher than 5, No. Pt: Indicates the total number of parame-146
ters studied.147
The acceptability limit would correspond to: IP ≥ 5148
Parameter proﬁle index (IPP) IPP = mean r ≥ 5 of all parameters149
Mean r = mean value of the parameters calculated.150
The acceptability limit would correspond to:151
IPP = mean r ≥ 5152
Good compression index (IGC) is calculated as follows:153
Good compression index(IGC)IGC = IPP × f (3)154
where f is the reliability factor and is calculated as follows:155
f = Polygonarea (4)156
Circle area157
The acceptability limit will be calculated by:158
IGC = IPP × f > 5. (5)159
3. Materials and methods160
3.1. Materials161
The active substance under study is Captopril (Farmahispania,162
Spain).163
The excipients that have been used for the study SeDeM164
were microcrystalline cellulose (Avicel® PH101, FMC Biopolymer165
(Norway)), barium sulfate (Panreac, Spain), ascorbic acid (Fagron,166
Spain), ethylcellulose (Ethylcellulose N100®, Aqualon, (USA)), and167
hydroxypropylmethylcellulose (HPMC K15 M Premium®, Colorcon,168
Inc. (USA)).169
Other ingredients used were talc (Fagron, Spain), magnesium170
stearate (Fagron, Spain), and colloidal silicon dioxide (Aerosil®,171
Fagron, (Spain)).172
3.2. Methods173
3.2.1. Preparation of the different formulations174
A formulation is presented for obtaining sustained release175
matrix tablets which can be obtained by direct compression. Given176
the characteristics of Captopril, it is decided to opt for a tablet177
consisting of ascorbic acid as the antioxidant which produces an178
acid pH in the gastrointestinal system to minimize the oxidation179
of Captopril, barium sulfate to give density to the tablet (Clarke180
et al., 1995) so that it is retained in the stomach, a combination181
of HPMC K15M Premium® and Ethylcellulose N100® to modulate182
the release of Captopril (Chattaraj and Das, 1996; Hjärtstam and183
Hjertberg, 1998; Ju et al., 2006; Katikaneni et al., 1995; Lin and Lin, 184
1995, 1996; Siepmann and Peppas, 2001; Upadrashta et al., 1993), 185
Avicel® PH101 to obtain a good cohesion, and magnesium stearate, 186
talc and Aerosil® to enhance the lubricity and ﬂow properties of 187
the formulation. 188
The manufacturing process of the formulations is as follows: 189
the raw materials are weighed individually into polyethylene bags. 190
Then the following raw materials are mixed in a polythene bag: 191
Captopril, ascorbic acid, talc, ethylcellulose N100®, HPMC K15 M 192
Premium®, barium sulfate and 70% of the Avicel® PH101. Subse- 193
quently the product is mixed manually for 2 min, it is sieved in a 194
0.8 mm sieve, it is transferred to a suitable container, and mixed 195
for 8 min  at 20 rpm in the Glatt biconical mixer. This intermediate 196
product is called mixture A. 197
In a plastic bag, 30% of the Avicel® PH101, Aerosil® and the mag- 198
nesium stearate are mixed by hand for 2 min. The product is sieved 199
in a 0.6 mm sieve and is incorporated to mixture A. Finally the prod- 200
uct is mixed at 20 rpm for 3 min  in the biconical Glatt drum. The 201
different formulations are shown in Table 3. 202
The experimental design used is the design of mixtures (Refs. 203
1 to 7), wherein the variables are the concentration of Ethylcel- 204
lulose N100® and of HPMC K15M Premium®, setting the other 205
components of the formula at 70% (w/w), with 30% (w/w)  being 206
the maximum concentration for each of the variables. 207
3.2.2. Tablets preparation 208
The blends were compressed in a Bonals® (Cornellà de Ll., 209
Spain) continuous eccentric press, provided with 19 mm × 10 mm 210
punches. 211
3.2.3. Tablets characterization 212
In the characterization of the tablets the methods applied were 213
resistance to crushing of tablets and Friability. 214
4. Results and discussions 215
4.1. SeDeM diagram results for the API and excipients 216
Fig.  1 shows the SeDeM diagram expert system of Captopril and 217
different excipients in the formula, and Table 4 shows the radius 218
obtained for each of the parameters studied. 219
Captopril has bulk and tapped density values that enable direct 220
compression technology as it represents 10% (w/w) in the formula: 221
however, it presents poor ﬂow and compressibility values, and so 222
the use of excipients presenting a good compressibility, such as 223
Avicel® PH101, Ethylcellulose N100® and HPMC K15M Premium®, 224
is critical. Avicel® PH101 is the excipient of the formula that has 225
the best compressibility due to its plastic behavior and its ability 226
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Table 3
Composition of the different formulations (Refs. 1–7).
Raw materials Percentage (%)
Ref. 1 Ref. 2 Ref. 3 Ref. 4 Ref. 5 Ref. 6 Ref. 7
Ethylcellulose N100® 30 25 20 15 10 5 0
HPMC  K15 M Premium® 0 5 10 15 20 25 30
Captopril 10 10 10 10 10 10 10
Talc 4 4 4 4 4 4 4
Aerosil® 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Magnesium stearate 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Avicel® PH101 25 25 25 25 25 25 25
Ascorbic acid 20 20 20 20 20 20 20
Barium sulfate 10 10 10 10 10 10 10
Total 100 100 100 100 100 100 100
Fig. 1. SeDeM diagram for the raw materials.
Table 4
Individual radius parameters, mean incidence values and parametric index for excipients and captopril.
Parameter/Incidence HPMC K15 M Premium® Ethylcellulose N100® Captopril Barium sulfate Ascorbic acid Avicel® PH101
Bulk density 3.24 3.32 4.30 9.95 5.75 3.12
Tapped density 4.59 3.76 6.04 10.00 6.65 4.16
Dimension 3.92 3.54 5.17 9.98 6.20 3.64
Inter-particle Porosity 7.57 2.93 5.58 1.92 1.96 6.68
Carr  index 5.88 2.34 5.76 4.59 2.71 5.00
Cohesion index 7.05 9.11 0.00 0.41 0.00 10.00
Compressibility 6.83 4.79 3.78 2.30 1.56 7.23
Hausner Ratio 7.92 9.34 7.98 8.52 9.22 8.34
Angle  of repose 3.23 3.78 2.96 3.91 3.09 3.62
Powder ﬂow 0.00 7.00 0.00 8.25 0.00 0.00
Flowability/powder ﬂow 3.71 6.71 3.65 6.89 4.10 3.98
Loss  on drying 5.45 8.62 9.56 9.96 10.00 4.81
Hygroscopicity 7.24 9.63 9.85 9.94 9.92 9.42
Lubricity/Stability 6.35 9.12 9.70 9.95 9.96 7.12
Particles <50 m 0.00 9.18 0.00 7.59 5.63 0.00
Homogeneity index 4.85 1.15 7.05 6.20 6.35 8.65
Lubricity/dosage  2.43 5.17 3.53 6.89 5.99 4.33
Good  compression index 4.52 5.57 4.69 6.44 4.86 5.06
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to generate hydrogen bridge bonds. Ethylcellulose N100® is more227
compressible than HPMC K15M® as it has a higher capacity of228
plastic deformation, although chemically it is less susceptible to229
make hydrogen bridge bonds and, by having a larger particle size,230
it presents less cohesive Van der Waals forces.231
The SeDeM diagram expert system predicts the galenic behavior232
of the formulations from the characteristics of the excipients. In233
this case, the radius values of the ﬁne particles and ﬂow of Avicel®234
PH101, HPMC K15M Premium® and Captopril exhibit very poor235
values, and so it was decided to incorporate 0.5% (w/w) of Aerosil236
in the formulations to optimize the ﬂow of the ﬁne particles. During237
compression of Captopril and ascorbic acid, adhesion on punches is238
observed, and thus a need was seen to incorporate an antiadherent239
in the formula such as talc at a concentration of 4% (w/w) and 0.5%240
(w/w) of magnesium stearate as a lubricant.241
4.2. SeDeM diagram results for the formulations242
Fig.  2 shows the SeDeM diagram expert system of the different243
formulations, and in Table 5 the radius for each of the parameters244
under study.245
Table 6 shows the results of friability and resistance of crushing246
of the tablets of each reference. The values of both the friability as247
the resistance of crushing are similar in all formulations, indicat-248
ing that there are no differences between the tablets in relation to249
these pharmacotechnical parameters when variation exists in the250
proportion of Ethylcellulose N100® with HPMC K15M®.251
4.2.1. Dimension252
There are no differences in the apparent and tapped density253
between the different formulations (Table 5). The radius of the254
dimension parameter of HPMC K15M® is 3.92 while that of the255
Ethylcellulose N100® is 3.54, so it is logical that as the percentage256
of HPMC K15M® in the formula increases, no differences between257
the apparent and tapped density are observed.258
4.2.2. Compressibility259
When the percentage of HPMC K15M® in the formula increases,260
the compressibility parameter and the radius values of the carr261
index, also increase. The cohesion index radii remain constant from262
formula 2–7 with values of 10. The cohesion index is higher as the263
percentage of HPMC K15M® increases. That is because the HPMC264
K15M® has  a particle size of <50 microns greater than the Ethylcel-265
lulose N100®. By decreasing particle size, the cohesive forces of the266
formula are higher due to the increase in Van der Waals forces and267
the increased contact surface area between the particles. Further-268
more, the HPMC K15M® has a higher percentage of water thereby269
increasing the capillary forces between the particles. The HPMC270
K15M® is more polar than the Ethylcellulose N100®, and so more271
hydrogen bridge bonds will be established with the other compo-272
nents of the formula, since being mainly polar components there273
will be more interaction between them.274
However, ethylcellulose N100® when compressed alone has275
better compressibility compared with HPMC K15M®. This means276
that the physicochemical properties of the HPMC K15M® are  more277
conducive to the compressibility of the formula by providing mois-278
ture that favors capillary forces between the particles and particle279
size, by increasing the contact surfaces and, consequently, the par-280
ticle bonds giving rise to tablets with greater hardness.281
4.2.3. Flowability/powder ﬂow282
By increasing the percentage of HPMC K15M®, the ﬂowabil-283
ity/powder ﬂow parameter decreases, obtaining a radius value of284
6.96 for formulation 1 and a radius value of 3.90 for formulation 7.285
This is because the HPMC K15M® has  a 51% of ﬁne particles <50 m286
compared to 4% of the Ethylcellulose N100®, and so when increas- 287
ing HPMC K15M® there are more Van der Waals interparticle forces 288
associated with particles of less than 50 m,  resulting in a greater 289
cohesion of the product thus decreasing the radius values of the 290
Hausner ratio parameters, angle of repose, and powder ﬂow. The 291
ﬂow behavior of formulation 1 is mass ﬂow, while when increasing 292
the percentage of HPMC K15M®, the ﬂow behavior changes to core 293
ﬂow. 294
Whereas all excipients have poor radius values in the ﬂow 295
parameter except ethylcellulose N100® and barium sulfate as 296
shown in Table 4, the incorporation of 0.5% Aerosil® was consid- 297
ered of great importance in the preformulation stage to achieve 298
correct powder ﬂow for the manufacture of direct compression 299
tablets, as shown in Table 5 in the radius values >5 obtained in 300
the Flowability/powder ﬂow parameter in formulations 1–4. 301
4.2.4. Lubricity/stability 302
The HPMC K15M® has  a higher percentage of humidity than 303
the ethylcellulose N100®, besides being more hygroscopic, and 304
hence increasing the percentage of HPMC K15M® also increases 305
the percentage of humidity and hygroscopicity of the formula. All 306
formulations present radius values of >5 in the lubricity/stability 307
parameter. However, when the percentage of HPMC K15M® 308
increases it is more likely that Captopril will oxidize resulting in 309
degradation products, because the formulation is more hygroscopic 310
and contains more moisture (Table 5). 311
4.2.5. Lubricity/dosage 312
When the percentage of HPMC K15M® is increased, the percent- 313
age of particles <50 m increases, obtaining radius values of 0 in 314
formulations 6 and 7, and of 2.15 in formulation 1. The radius values 315
in the dosage/lubricity parameter vary between 1 and 2 (Table 5). 316
Formulation 7 is the one that has a more narrow distribution 317
of particle size, and is therefore the formulation that has a higher 318
radius value in the homogeneity index parameter. 319
The high percentage of ﬁne particles is the major cause of the 320
poor ﬂow of formulations 4, 5, 6 and 7 (Table 5). 321
4.2.6. Good compression index 322
The IGC values obtained for each formulation designed (Ref. 323
1 to Ref. 7) were processed statistically using Statgraphics Cen- 324
turion XVI software. The results have been adjusted to a simple 325
linear regression model considering the good compression index 326
as dependent variable and the formulations as independent vari- 327
able resulting in an r2 = 0.9532, the results of which are shown in 328
Table 7. 329
Since the p-value in the ANOVA table is less than 0.05, there 330
is a statistically signiﬁcant relationship between good compres- 331
sion index and Formulations with a conﬁdence level of 95.0%. 332
The R-squared statistic indicates that the adjusted model explains 333
95.3232% of the variability in good compression index. The correla- 334
tion coefﬁcient is equal to −0.976336, indicating a relatively strong 335
relationship between variables. Standard error of the estimate indi- 336
cates that the standard deviation of residuals is 0.077127. The mean 337
absolute error (MAE) of 0.0591837 is the average value of the resid- 338
ual. The Durbin–Watson (DW) statistic examines the residuals to 339
determine if there is any signiﬁcant correlation. Since the p-value 340
is greater than 0.05, there is no indication of serial autocorrelation 341
in the residuals with a conﬁdence level of 95.0%. 342
Fig.  3 shows the values of the good compression index, adjusting 343
to a linear equation to describe the relationship between the good 344
compression index and formulations. 345
In order to ﬁnd the linear regression that best adjusts to the 346
results obtained, we have considered a total of 27 models, and the 347
one that best adjusts is the squared Y square root X model, giving 348
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Fig. 2. SeDeM diagram for the different formulations.
Table 5
Radius parameters, mean incidence values and parametric index for the different formulations.
Parameter/incidence Formulations
1 2 3 4 5 6 7
Bulk density 4.48 4.42 4.64 4.42 4.28 4.15 4.32
Tapped density 6.15 5.59 5.85 5.87 5.93 5.83 5.96
Dimension 5.32 5.01 5.25 5.15 5.11 4.99 5.14
Inter-particle Porosity 5.05 3.95 3.72 4.66 5.42 5.78 5.31
Carr  index 5.43 4.19 4.14 4.94 5.57 5.76 5.50
Cohesion index 9.03 10.00 10.00 10.00 10.00 10.00 10.00
Compressibility 6.50 6.05 5.95 6.53 6.99 7.18 6.94
Hausner ratio 8.14 8.68 8.70 8.36 8.07 7.98 8.10
Angle  of repose 4.24 3.88 3.34 3.89 3.71 3.53 3.59
Powder ﬂow 8.50 7.67 6.50 4.67 0.00 0.00 0.00
Flowability/powder ﬂow 6.96 6.74 6.18 5.64 3.93 3.83 3.90
Loss  on drying 9.00 8.69 8.48 8.09 7.61 7.70 7.51
Hygroscopicity 9.69 9.75 9.72 9.67 9.64 9.45 8.57
Lubricity/stability 9.34 9.22 9.10 8.88 8.62 8.58 8.04
Particles <50 m 2.15 1.82 1.59 1.34 0.92 0.00 0.00
Homogeneity index 1.20 1.40 1.45 1.50 2.45 2.50 3.45
Lubricity/dosage 1.67 1.61 1.52 1.42 1.68 1.25 1.73
Good  compression index 5.80 5.56 5.40 5.35 5.04 4.97 4.94
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Table 6
Friability and rupture strength values obtained in the different formulations.
Formulations
1 2 3 4 5 6 7
Friability (%) 0.39 0.39 0.32 0.24 0.32 0.33 0.35
Rupture strength (Newtons) 172 ± 16 169 ± 20 174 ± 25 169 ± 62 161 ± 58 1774 ± 30 195 ± 25
Table 7
Results of adjusted to simple linear regression model of the IGC.
Coefﬁcients
Least squares Standard t-Statistic
Parameter Estimates Error p-Value
Intercept 5.88286 0.0651842 90.2497 0.0000
Slope −0.147143 0.0145756 −10.0951 0.0002
Analysis of variance
Source Sum of squares Df Mean square F-statistic p-Value
Model 0.606229 1 0.606229 101.91 0.0002
Residual 0.0297429 5 0.00594857
Total (corr.) 0.635971 6
Correlation coefﬁcient = −0.976336.
R-squared = 95.3232%.
R-squared (adjusted for d.f.) = 94.3879%.
Standard error of EST. = 0.077127.
Mean absolute error = 0.0591837.
Durbin–Watson statistic = 2.16591 (p = 0.3682).
Lag  1 residual autocorrelation = −0.280088.
The equation of the adjusted model is as follows:
Good compression index=5.88286− 0.147143 × Formulations.
a correlation coefﬁcient of 0.9852 and an r2 = 0.9707 the results of349
which are shown in Table 8.350
Since the p-value in the ANOVA table is less than 0.05, there351
is a statistically signiﬁcant relationship between good compres-352
sion index and formulations with a conﬁdence level of 95.0%.353
The R-squared statistic indicates that the adjusted model explains354
97.0704% of the variability in good compression index after being355
transformed to a logarithmic scale to linearize the model. The cor-356
relation coefﬁcient is equal to −0.985243, indicating a relatively357
strong relationship between variables. Standard error of the esti-358
mate indicates that the standard deviation of residuals is 0.651761.359
The mean absolute error (MAE) of 0.440439 is the average value360
of the residual. The Durbin–Watson (DW) statistic examines the361
Fig. 3. Good compression index (simple linear model).
residuals to determine if there is any signiﬁcant correlation. Since 362
the p-value is greater than 0.05, there is no indication of serial 363
autocorrelation in the residuals with a conﬁdence level of 95.0%. 364
Fig.  4 shows the values of the good compression index adjusting 365
the equation with the squared Y square root X model to describe 366
the relationship between the good compression index and formu- 367
lations. 368
The squared Y square root X model is the one which gives the 369
highest value of R-Square at 97.0704%, that is 1.74717% higher than 370
the linear model. 371
Formulation 1 is the one with the best good compression index 372
with a radius value of 5.80, while formula 7 has a radius value of 373
4.94. 374
There is an almost linear relationship between the different for- 375
mulations in the good compression index parameter. Increasing the 376
percentage of HPMC K15M® causes an increase in the percentage 377
Table 8
Results of adjusted to squared Y square root X regression model of the IGC.
Coefﬁcients
Least squares Standard t-Statistic
Parameter Estimates Error p-Value
Intercept 39.3994 0.91026 43.2837 0.0000
Slope  −5.85815 0.45513 −12.8714 0.0001
Analysis of variance
Source Sum of squares Df Mean square F-statistic p-Value
Model  70.3763 1 70.3763 165.67 0.0001
Residual 2.12396 5 0.424793
Total (corr.) 72.5003 6
Correlation coefﬁcient = −0.985243.
R-squared = 97.0704%.
R-squared (adjusted for d.f.) = 96.4845%.
Standard error of EST. = 0.651761.
Mean absolute error = 0.440439.
Durbin–Watson statistic = 2.62428 (p = 0.6542).
Lag 1 residual autocorrelation = −0.374093.
The equation of the adjusted model is as follows:
Good compression index = sqrt(39.3994 − 5.85815 × sqrt(Formulations)).
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Fig. 4. Good compression index (Y-square-X square root model).
of ﬁne particles which hinders the ﬂow of the powder, in addition378
to increasing the humidity and the hygroscopicity of the formula,379
thereby increasing the percentage of HPMC K15M® in the formula,380
the radius value of the good compression index decreases linearly381
as shown in Figs. 3 and 4.382
Accordingly, the greater the percentage of ethylcellulose N100®383
there is in the formulation and the lower that of HPMC K15M®, the384
powder mixture will have better characteristics for direct compres-385
sion.386
5. Conclusions387
1. The SeDeM Diagram is a useful tool for the galenic characteriza-388
tion of excipients and drugs with respect to their suitability for389
direct compression.390
2. The SeDeM Diagram is a useful tool for the design of experiments,391
using the values of the radius of the formulations in the Good392
compression index parameter as the critical quality attribute for393
the study of the system.394
3. Formulation 1 is the best formulation for direct compression of395
Captopril, with a radius value of 5.80 in the good compression396
index parameter.397
4. There is an almost linear relationship in the radii of good com-398
pression index according to the percentage of ethylcellulose399
N100® and HPMC K15M® among the 7 formulations in the linear400
model and in the Y-square X-square root model.401
5. The SeDeM Diagram is a useful tool to observe the behavior of402
the system, if it is linear, or if there are any interactions between403
the factors.
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